REDCARE PHARMACY NV |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 130 EUR | 0.00% |
|
+0.78% | -1.22% |
| Apr. 26 | REDCARE PHARMACY : Deutsche Bank reiterates its Buy rating | ZD |
| Apr. 26 | REDCARE PHARMACY : Hauck & Aufhauser keeps its Buy rating | ZD |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 585.7 | 2,658 | 2,050 | 798.2 | 2,395 | 2,626 | - | - |
| Enterprise Value (EV) 1 | 621.6 | 2,568 | 2,039 | 986.6 | 2,395 | 2,780 | 2,761 | 2,716 |
| P/E ratio | -15.6 x | -127 x | -27.3 x | -10.2 x | -180 x | -298 x | 67.8 x | 36.3 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 0.84 x | 2.75 x | 1.93 x | 0.66 x | 1.33 x | 1.1 x | 0.9 x | 0.74 x |
| EV / Revenue | 0.89 x | 2.65 x | 1.92 x | 0.82 x | 1.33 x | 1.17 x | 0.95 x | 0.77 x |
| EV / EBITDA | -45.8 x | 119 x | -408 x | -123 x | 44.8 x | 39 x | 23.3 x | 15.5 x |
| EV / FCF | -13.8 x | -72.3 x | -64.7 x | -11.9 x | 103 x | -511 x | 118 x | 40.6 x |
| FCF Yield | -7.26% | -1.38% | -1.55% | -8.38% | 0.97% | -0.2% | 0.85% | 2.46% |
| Price to Book | 2.44 x | 6.91 x | 4.94 x | 2.26 x | - | 4.67 x | 4.39 x | 3.92 x |
| Nbr of stocks (in thousands) | 13,464 | 17,935 | 18,095 | 18,095 | 18,199 | 20,203 | - | - |
| Reference price 2 | 43.50 | 148.2 | 113.3 | 44.11 | 131.6 | 130.0 | 130.0 | 130.0 |
| Announcement Date | 3/17/20 | 3/3/21 | 3/2/22 | 3/7/23 | 3/5/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 701 | 968.1 | 1,060 | 1,204 | 1,799 | 2,379 | 2,905 | 3,527 |
| EBITDA 1 | -13.57 | 21.62 | -5 | -8.044 | 53.5 | 71.28 | 118.4 | 175.1 |
| EBIT 1 | -28.18 | 5.556 | -32.3 | -47.55 | -3.793 | 10.32 | 50.43 | 107.8 |
| Operating Margin | -4.02% | 0.57% | -3.05% | -3.95% | -0.21% | 0.43% | 1.74% | 3.06% |
| Earnings before Tax (EBT) 1 | -42.18 | -15.93 | -77.88 | -84.12 | -14.35 | -7.26 | 61.69 | 106.3 |
| Net income 1 | -36.27 | -16.77 | -74.2 | -77.65 | -12.04 | -9.267 | 45.75 | 77.13 |
| Net margin | -5.17% | -1.73% | -7% | -6.45% | -0.67% | -0.39% | 1.57% | 2.19% |
| EPS 2 | -2.780 | -1.170 | -4.150 | -4.320 | -0.7300 | -0.4356 | 1.919 | 3.583 |
| Free Cash Flow 1 | -45.11 | -35.53 | -31.52 | -82.64 | 23.24 | -5.443 | 23.47 | 66.83 |
| FCF margin | -6.43% | -3.67% | -2.97% | -6.86% | 1.29% | -0.23% | 0.81% | 1.89% |
| FCF Conversion (EBITDA) | - | - | - | - | 43.43% | - | 19.82% | 38.17% |
| FCF Conversion (Net income) | - | - | - | - | - | - | 51.3% | 86.65% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/17/20 | 3/3/21 | 3/2/22 | 3/7/23 | 3/5/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2021 Q4 | 2021 S2 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2022 S2 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2024 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 534.4 | 288 | 525.9 | 305 | 287 | 592 | 284.5 | 327.8 | 612.3 | 372.1 | 419.9 | 791.9 | 475.5 | 560.2 |
| EBITDA 1 | 6.9 | -10 | -11.9 | -4 | -5 | -9 | 1.256 | 1.133 | 2.389 | 8.763 | 13.25 | 22.01 | 15.25 | 11.75 |
| EBIT | - | -18.6 | - | - | - | - | -9.509 | - | - | - | - | - | -21.64 | - |
| Operating Margin | - | -6.46% | - | - | - | - | -3.34% | - | - | - | - | - | -4.55% | - |
| Earnings before Tax (EBT) | - | -46.24 | - | - | - | - | - | - | - | - | - | - | 8.899 | - |
| Net income | - | -42.5 | - | - | - | - | - | - | - | - | - | - | 9.11 | - |
| Net margin | - | -14.76% | - | - | - | - | - | - | - | - | - | - | 1.92% | - |
| EPS | - | -2.350 | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/5/21 | 3/2/22 | 3/2/22 | 5/5/22 | 8/3/22 | 8/3/22 | 10/31/22 | 3/7/23 | 3/7/23 | 5/2/23 | 8/1/23 | 8/1/23 | 10/31/23 | - |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 36 | - | - | 188 | - | 154 | 135 | 90.1 |
| Net Cash position 1 | - | 90 | 11 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -2.65 x | - | - | -23.42 x | - | 2.154 x | 1.14 x | 0.5143 x |
| Free Cash Flow 1 | -45.1 | -35.5 | -31.5 | -82.6 | 23.2 | -5.44 | 23.5 | 66.8 |
| ROE (net income / shareholders' equity) | -16.2% | -5.1% | -17.7% | -20.2% | - | 0.82% | 6.55% | 11.5% |
| ROA (Net income/ Total Assets) | -9.33% | -3.5% | -11.2% | -10.3% | - | -0.16% | 4.18% | 6.42% |
| Assets 1 | 388.9 | 479.2 | 660.1 | 756.3 | - | 5,649 | 1,093 | 1,201 |
| Book Value Per Share 2 | 17.80 | 21.50 | 23.00 | 19.50 | - | 27.80 | 29.60 | 33.20 |
| Cash Flow per Share 2 | -2.320 | 1.240 | 0.6500 | -1.620 | 3.190 | 3.260 | 5.180 | 7.170 |
| Capex 1 | 14.7 | 53.3 | 43.2 | 53.5 | 38.2 | 56.8 | 65.3 | 68.7 |
| Capex / Sales | 2.1% | 5.51% | 4.07% | 4.44% | 2.12% | 2.39% | 2.25% | 1.95% |
| Announcement Date | 3/17/20 | 3/3/21 | 3/2/22 | 3/7/23 | 3/5/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
130
EUR
Average target price
155.2
EUR
Spread / Average Target
+19.37%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -1.22% | 2.8B | |
| -32.21% | 15.27B | |
| -31.97% | 10.84B | |
| -30.42% | 6.06B | |
| +8.14% | 6.04B | |
| -11.41% | 5.86B | |
| -0.88% | 4.71B | |
| +52.19% | 4.29B | |
| -12.31% | 3.61B | |
| -14.86% | 3.33B |
- Stock Market
- Equities
- RDC Stock
- Financials Redcare Pharmacy NV
